Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 15% revenue increase and improved gross margins. The strategic outlook is optimistic, focusing on future-oriented initiatives. Despite acknowledging risks, the growth in net income and cash flow supports a positive sentiment. Given the small market cap, the stock is likely to react positively within the 2% to 8% range.
Key Financial Performance
Revenue $120 million, a 15% increase year-over-year, driven by strong demand for our core products and successful execution of our commercial strategy.
Gross Margin 75%, up from 72% in the prior year, reflecting improved operational efficiencies and favorable product mix.
Operating Expenses $45 million, a 5% increase year-over-year, primarily due to increased investment in R&D and marketing initiatives.
Net Income $25 million, a 20% increase year-over-year, attributed to higher revenue and improved gross margin.
Cash Flow from Operations $30 million, a 10% increase year-over-year, supported by strong collections and disciplined expense management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements involve risks and uncertainties, which could lead to future results differing materially from current expectations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: The focus is on future-oriented strategic plans, including product launches, market trends, and operational changes.
Forward-looking Statements: The company provides projections, expectations, and trends for future performance and market conditions, including revenue expectations, margin projections, capital expenditures, market trends, and business segment performance.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Amsellem Piper
Belanger Needham
Brandon Folkes
CFO Brandon
Co LLC
Colleen Tupper
Director Scott
Division Amsellem
Division EDT
Division Jeevan
Division Serge
Dreyer Executive
EDT Greetings
Executive VP
Folkes HC
HC Wainwright
Jeevan Larson
LLC Research
Larson Truist
Officer Colleen
Pharmaceutical Conference
Piper Sandler
President Director
Relations CEO
Research Division
Sandler Co
Scott Dreyer
Serge Belanger
Tupper Executive
VP CFO
Wainwright Co
conference Head
COLL Transcript
Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial performance with a 15% revenue increase and improved gross margins. The strategic outlook is optimistic, focusing on future-oriented initiatives. Despite acknowledging risks, the growth in net income and cash flow supports a positive sentiment. Given the small market cap, the stock is likely to react positively within the 2% to 8% range.
Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary and Q&A indicate a positive sentiment. The company reported strong financial performance, with revenue and EBITDA growth, and raised 2025 guidance. Despite increased operational costs, the strategic focus on Jornay PM and share repurchases is promising. The Q&A highlighted stable demand and no significant competitive threats. However, some management responses were vague, slightly tempering enthusiasm. With a market cap of $1.06 billion, the stock is likely to see a positive reaction, between 2% to 8%, given the strong growth and strategic initiatives.
Collegium Pharmaceutical, Inc. (COLL) Q3 2025 Earnings Call Transcript
Positive11-6
The company reported record high revenue and strong earnings, coupled with optimistic guidance and a raised financial outlook. Despite some uncertainties in strategic execution and M&A specifics, the market is likely to react positively due to robust financial performance, a significant share repurchase program, and strategic growth initiatives. Given the company's small-cap status, these factors are expected to drive a positive stock price movement in the short term.
COLL Slides
COLL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
